Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF1K16 Combined With Bevacizumab in Recurrent or Progressive Glioma
NCT07678684Phase 2Recruiting
- Sponsor
- HighField Biopharmaceuticals
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of HF1K16 in glioma, sponsored by HighField Biopharmaceuticals. Started Jun 2026; status: recruiting.
02
Drugs
HF1K16
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07678684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678684.